ClinicalTrials.gg
Not yet recruitingNCT06060886SchizOMICSUpdated Sep 29, 2023

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

A Phase 4 interventional study of Aripiprazole and Paliperidone in Schizophrenia, Treatment-resistant Schizophrenia and Side Effect, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Not yet recruiting. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-09-29.

Primary conditionSchizophrenia, Treatment-ResistantRegistry: SchizophreniaReclassifiedWhy we changed it
Registry
Schizophrenia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Schizophrenia, Treatment-Resistant
Why
  1. The study's listed conditions name Schizophrenia, Treatment-Resistant, a narrower term within Schizophrenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
244
Allocation
Not applicable
Ages
15 Years to 40 Years
Sex
All
01

Study summary

SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first psychotic episode. The trial will include a total of 244 patients, with two arms of treatment with paliperidone and aripiprazole (1:1).

The main objectives of the study are:

  1. To compare the efficacy and safety of aripiprazole and paliperidone in the treatment of first episode psychosis (FEP) subjects in real-world clinical settings at 3 months.
  2. To elucidate whether non-responders after 3 months of adequate treatment may display different molecular signatures at baseline based on multi omics data and systems biology analysis.
  3. To uncover whether the appearance of side effects after 1 year of adequate treatment may be related to different molecular signatures based on multi-omics data and lifestyle phenotype using systems biology analysis.
02

Conditions studied

  • Schizophrenia
  • Treatment-resistant Schizophrenia
  • Side Effect
  • Lipid Metabolism Disorders
  • Diabetes
  • NAFLD
  • Psychosis
03

In context

Schizophrenia, Treatment-Resistant Reclassified

54 studies on the registry are indexed under Schizophrenia, Treatment-Resistant; 23 are open to participants now.

This study's planned enrollment of 244 is above the median of 60 across 46 interventional studies indexed under Schizophrenia, Treatment-Resistant.

Browse Schizophrenia, Treatment-Resistant studies →

Lead sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.

Compared within Schizophrenia, Treatment-Resistant, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Schizophrenia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 15-40 years;
  2. living in the catchment area;
  3. experiencing a first episode of psychosis;
  4. no prior treatment with antipsychotic medication or, if previously treated, a total lifetime of adequate antipsychotic treatment of less than 6 weeks;
  5. fth Edition (DSM-5) criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder.

Exclusion criteria

Exclusion Criteria:

  1. meeting criteria for drug dependence;
  2. meeting DSM-IV criteria for mental retardation;
  3. having a history of neurological disease or head injury.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
244 participants (estimated)

Study arms

  • Experimental
    First episode of psychosis patients

    Operational definition for a "first episode of psychosis" included individuals with a non-affective psychosis who have not received previous antipsychotic treatment regardless of the duration of psychosis.

    Drug: Aripiprazole · Drug: Paliperidone

Interventions

  • Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.

  • Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence

06

What researchers measure

Primary outcomes

  1. Number of patients with a therapeutic response to aripiprazole or paliperidone

    Considering response as a reduction in the Positive and Negative Symptom Scale (PANSS) \> 50%. PANSS is a test made up of 30 items that are scored from 1 (absent) to 7 (extreme).

    Time frame: 3 months

  2. Number of patients with a therapeutic response to aripiprazole or paliperidone

    Considering response as Clinical Global Impression severity scale for schizophrenia (ICG-ESQ-SI) \< 4 points. ICG-ESQ-SI is a test made of 5 items that are scored from 1 (absent) to 7 (extreme).

    Time frame: 3 months

Secondary outcomes

  1. Number of patients with changes in negative symptoms

    Using Scale for the Assessment of Negative Symptoms (SANS), test made of 25 items that are scored from 1 (absent) to 5 (extreme).

    Time frame: 12 months

  2. Number of patients with changes in depressive symptoms

    Using Calgary Depression Scale for Schizophrenia (CDSS), test made of 9 items that are scored from 1 (absent) to 4 (extreme).

    Time frame: 12 months

  3. Number of patients with changes in functionality

    Using Personal and Social Performance scale (PSP), test made of 4 items that are scored from 1 (absent) to 6 (extreme).

    Time frame: 12 months

  4. Number of patients with changes in quality of life

    Using EuroQoL, test made of 1 item that are scored from 0 (worst) to 100 (best).

    Time frame: 12 months

  5. Number of patients with side effects

    Using UKU Side Effect Rating Scale, test made of 56 items that are scored from 0 (absent) to 3 (extreme).

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2023; primary completion for Jun 2025, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Sep 29, 2023
StartEst.
Nov 1, 2023
Primary completionEst.
Jun 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06060886
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Sep 29, 2023
Start date
Nov 1, 2023 (estimated)
Primary completion
Jun 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 29, 2023

Study contacts

Alba Toll Privat, MD, PhD
Contact
albatollprivat@gmail.com
0034 937 41 77 00 ext. 4754
Projects Department (CIBER)
Contact
proyectos@ciberisciii.es
+34918222874
Javier Labad Arias, MD, PhD
principal investigator · Consorci Sanitari del Maresme, Hospital de Mataró

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aripiprazole · Paliperidone

Start the discussion